FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment

MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms

India’s pharma market to hit US$ 130 billion, exports US$ 80 billion by 2030: ASSOCHAM

Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion

Bayer’s asundexian moves into EU regulatory review as stroke prevention race intensifies

The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy

Alembic Pharma receives USFDA tentative approval for generic Larotrectinib capsules

Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.

AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab

Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer

AmMax Bio licenses Lonza’s ADC tech to advance AML candidate AMB-104

The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027

FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough

The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year

GSK bets big on oncology with $10.6 billion Nuvalent acquisition

Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio

Lupin partners with LABORATORIOS ERN to launch Luforbec in Spain

Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials